Cargando…
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial
SIMPLE SUMMARY: Diffuse large B-cell lymphoma (DLBCL) is an aggressive, heterogeneous non-Hodgkin B lymphoma, that 35% of cases produces relapsed/refractory (R/R) disease. At this point, the search of prognostic and predictive factors in DLBCL is indispensable through key biomarkers. Recently, we ha...
Autores principales: | Jiménez-Cortegana, Carlos, Sánchez-Martínez, Pilar M., Palazón-Carrión, Natalia, Nogales-Fernández, Esteban, Henao-Carrasco, Fernando, Martín García-Sancho, Alejandro, Rueda, Antonio, Provencio, Mariano, de la Cruz-Merino, Luis, Sánchez-Margalet, Víctor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471526/ https://www.ncbi.nlm.nih.gov/pubmed/34572849 http://dx.doi.org/10.3390/cancers13184622 |
Ejemplares similares
-
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
por: Palazón-Carrión, Natalia, et al.
Publicado: (2022) -
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
por: Jiménez-Cortegana, Carlos, et al.
Publicado: (2021) -
Osteoradionecrosis GDP survey
por: Shah, A., et al.
Publicado: (2020) -
Nowcasting Japan’s GDP
por: Hayashi, Fumio, et al.
Publicado: (2022) -
Getting to Grips with China's GDP Data
por: Orlik, Thomas
Publicado: (2011)